Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
+$0.04 today
- Market cap
- $227.58M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
Volume 4.13M
Average 3.33M
CABA Interest Income
Income earned on cash, deposits, and investments held by the company.
Cabaletta Bio, Inc.NASDAQ: CABA
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income declines year over year
Q1 FY2026 interest income of $1.08M fell 27.6% year over year, ahead of the -34.1% change in trailing-twelve-month interest income. Sequentially, it fell 18.9% from the prior quarter. Over 3 fiscal years it compounded at +73.0% a year.
Context
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -27.6% holds above the trailing-twelve-month pace of -34.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 6.03M USD
- Year-over-year change
- -39.8%
- 4-year CAGR
- +298.1%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.03M | -39.8% |
| FY2024 | 2024-12-31 | 10.03M | +43.5% |
| FY2023 | 2023-12-31 | 6.99M | +500.1% |
| FY2022 | 2022-12-31 | 1.16M | +4750.0% |
| FY2021 | 2021-12-31 | 24K | — |
Interest Income vs competitors
How CABA compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -34.1% is the 5th highest of 11, against a peer median of -40.1%.
- Over three fiscal years its annual growth of +73.0% compares with a peer median of +64.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $17.35M USD | -14.3% | +61.7% | — | |
| LTM Mar 2026 | $14.02M USD | -40.6% | +13.7% | — | |
| LTM Mar 2026 | $11.41M USD | -45.9% | +22.9% | 36812.9% | |
| LTM Mar 2026 | $8.6M USD | -44.4% | +152.5% | — | |
| LTM Mar 2026 | $8.43M USD | +242.7% | +128.9% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $7.09M USD | -0.4% | +66.6% | — |
| LTM Mar 2026 | $5.62M USD | -34.1% | +73.0% | — | |
| FY2025 | A$5.25M AUD | +35.2% | +186.0% | 104.1% | |
| LTM Mar 2026 | $2.26M USD | -39.6% | -0.5% | 111.9% | |
| LTM Mar 2026 | €852.58K EUR | -60.2% | +176.5% | 6.3% | |
| LTM Mar 2026 | -$1.51M USD | -112.9% | +14.6% | 3.9% | |
| Peer median (excluding CABA) | — | -40.1% | +64.1% | 104.1% | |
Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.49M | 39.3M | 55.42M | 97.2M | 142.67M |
| Selling, General & Admin | 13.82M | 14.84M | 19.24M | 27.94M | 29.57M |
| Operating Expenses | 46.31M | 54.14M | 74.66M | 125.14M | 172.24M |
| Depreciation & Amortization | 733K | 1.18M | 1.43M | 1.71M | 1.65M |
| EBITDA | (45.56M) | (51.8M) | (66.25M) | (113.41M) | (164.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (46.31M) | (54.14M) | (74.66M) | (125.14M) | (172.24M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 24K | 1.16M | 6.99M | 10.03M | 6.03M |
| Interest Expense | 0 | 0 | 0 | 748K | 2M |
| Other Income / Expenses | 24K | 1.16M | 6.99M | 9.28M | 4.39M |
| Income Before Tax | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| EPS (Diluted) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| Weighted Avg Shares | 25.74M | 29.34M | 40.95M | 49.52M | 102.26M |
| Weighted Avg Shares (Diluted) | 25.74M | 29.34M | 40.95M | 49.47M | 102.26M |
Cabaletta Bio, Inc.
NASDAQ:CABA
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.